Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326454 · ClinicalTrials.gov registry record · Phase 2
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Light Sciences Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT02326454: Completed Phase 2 study, sponsored by Light Sciences Oncology.
NCT02326454 is a Phase 2 study that has completed, run by Light Sciences Oncology. The registered enrollment target is 225 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326454, a Phase 2 study, has completed, sponsored by Light Sciences Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device. MR901 is a code used to identify the combination of talaporfin sodium and the drug-activating device. Two different light doses will be tested against placebo groups in this 4-arm study.
Primary Outcome
Change from baseline in the total International Prostate Symptom Score (IPSS, Questions 1-7)
Interventions
- DRUG Saline
- DRUG talaporfin sodium
- DEVICE Drug Activator 100 J/cm
- DEVICE Drug Activator 200 J/cm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-03-29 |
| Phase | Phase 2 |
What the finished NCT02326454 record still lists
NCT02326454 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT02326454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02326454 about?
NCT02326454 is a clinical study titled "A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia". This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device. MR901 is a code used to identify the combination of talaporfin sodium and the drug-activating device. Two different light doses will be tested a...
What is the current status of trial NCT02326454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2014-11. Estimated completion is 2017-03-29.
What interventions are being tested in trial NCT02326454?
The interventions under investigation include: Saline (DRUG), talaporfin sodium (DRUG), Drug Activator 100 J/cm (DEVICE), Drug Activator 200 J/cm (DEVICE).
Who is sponsoring clinical trial NCT02326454?
This trial is sponsored by Light Sciences Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02326454's enrollment target sits among peer trials
225 267th of 2000 higher than 1,732 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia